Ask AI

ClinicalThought

Share

Program Content

Activities

  • PI3K/AKT Inhibitors in mBC
    Novel Targeted Therapies for PIK3CA/AKT1/PTEN-Altered Metastatic Breast Cancer: Key Evidence and Real-world Insights to Optimize Patient Care
    Clinical Thought
    Congratulations: You achieved a completion on 04/09/2022

    Released: September 29, 2025

  • PI3K/AKT-hämmare i metastatisk bröstcancer
    Nya riktade behandlingar för metastatisk bröstcancer med PIK3CA/AKT1/PTEN-förändringar: Viktig evidens och insikter från klinisk praxis för att optimera patientvården
    Clinical Thought
    Congratulations: You achieved a completion on 04/09/2022

    Released: October 13, 2025

  • Inibidores de PI3K/AKT no mBC
    Novas terapias direcionadas para o cancro da mama metastático com alterações em PIK3CA/AKT1/PTEN: evidências importantes e insights do mundo real para otimizar o tratamento de doentes
    Clinical Thought
    Congratulations: You achieved a completion on 04/09/2022

    Released: October 13, 2025

  • PI3K/AKT-Inhibitoren bei mbH (metastasierter Brustkrebs)
    Neue zielgerichtete Therapien bei PIK3CA/AKT1/PTEN-verändertem metastasiertem Brustkrebs: Zentrale Evidenz und Erkenntnisse aus der Versorgungspraxis (Real-World-Daten) zur Optimierung der Patientenversorgung
    Clinical Thought
    Congratulations: You achieved a completion on 04/09/2022

    Released: October 15, 2025

  • Inibitori di PI3K/AKT nel mBC
    Nuove terapie mirate per il carcinoma mammario metastatico con alterazioni dei geni PIK3CA/AKT1/PTEN: prove determinanti e approfondimenti dal mondo reale per ottimizzare la cura dei pazienti
    Clinical Thought
    Congratulations: You achieved a completion on 04/09/2022

    Released: October 16, 2025

  • Inhibiteurs de PI3K/AKT dans le cancer du sein métastatique
    Nouveaux traitements ciblés pour le cancer du sein métastatique avec altération des gènes PIK3CA/AKT1/PTEN : des preuves essentielles et des informations concrètes pour optimiser les soins
    Clinical Thought
    Congratulations: You achieved a completion on 04/09/2022

    Released: October 16, 2025

  • PI3K AKT Therapies for HRpos HER2neg ABC
    Where We Are Today and Where We Are Going: Integrating PI3K/AKT Pathway–Directed Therapies Into Clinical Practice for Hormone Receptor–Positive/HER2-Negative Advanced Breast Cancer
    Clinical Thought
    Congratulations: You achieved a completion on 04/09/2022

    Released: July 13, 2026

  • PI3K AKT-behandlingsalternativ för HRpos HER2neg ABC
    Där vi är idag och där vi är på väg: Integrering av PI3K/AKT-signalvägs–styrda behandlingsalternativ i kliniska praxis för patienter med hormonreceptor–positiv/HER2-negativ lokalt bröstcancer
    Clinical Thought
    Congratulations: You achieved a completion on 04/09/2022

    Released: August 16, 2026

  • Terapie mirate su PI3K/AKT per il carcinoma mammario avanzato HR-pos/HER2-neg
    Situazione attuale e prospettive future: integrazione delle terapie mirate alla via di segnale PI3K/AKT nella pratica clinica per il carcinoma mammario avanzato positivo per i recettori ormonali e HER2-negativo
    Clinical Thought
    Congratulations: You achieved a completion on 04/09/2022

    Released: August 16, 2026

  • Thérapies ciblant PI3K/AKT dans le CSM RH+ et HER2neg ABC
    Où nous en sommes et où nous allons : Intégration des thérapies ciblant la voie PI3K/AKT dans la pratique clinique pour le cancer du sein avancé à récepteurs hormonaux positifs/HER2 négatif
    Clinical Thought
    Congratulations: You achieved a completion on 04/09/2022

    Released: August 16, 2026

  • Terapias PI3K AKT para ABC HRpos HER2neg
    Onde estamos e para onde vamos: integração de terapêuticas dirigidas à via PI3K/AKT na prática clínica para o cancro da mama avançado com recetores hormonais positivos e HER2 negativo
    Clinical Thought
    Congratulations: You achieved a completion on 04/09/2022

    Released: August 17, 2026

  • PI3K-AKT-Therapien für HR+ HER2- ABC
    Wo wir heute stehen und in welche Richtung bewegen wir uns: Integration von PI3K/AKT-Signalweg-gerichteten Therapien in die klinische Praxis für Hormonrezeptor-positiven/HER2-negativen fortgeschrittenen Brustkrebs (ABC)
    Clinical Thought
    Congratulations: You achieved a completion on 04/09/2022

    Released: August 24, 2026

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC.

Supporters

Supported by an educational grant from F. Hoffmann-La Roche Ltd.

F. Hoffmann-La Roche Ltd.